All IndicationsMetabolic & EndocrinePhase 3Phase 3Phase 3Phase 3Phase 2Phase 2Phase 2
⚡
Obesity
6
Companies
7
Drug Programs
4
Phase 3
0
Upcoming PDUFAs
Competitors
SNY
Sanofi
rimonabant (SR141716)
NVO
Novo Nordisk A/S
Semaglutide 1.0 mg
RHHBY
Roche Holding AG
RO7204239
LLY
Eli Lilly and Company
Retatrutide
SNY
Sanofi
SR147778
IONS
Ionis Pharmaceuticals, Inc.
ISIS-FGFR4RX
SKYE
Skye Bioscience, Inc.
Nimacimab injection
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| SNY Sanofi | rimonabant (SR141716) | Phase 3 | — | — | — |
| NVO Novo Nordisk A/S | Semaglutide 1.0 mg | Phase 3 | — | — | — |
| RHHBY Roche Holding AG | RO7204239 | Phase 3 | — | — | — |
| LLY Eli Lilly and Company | Retatrutide | Phase 3 | — | — | — |
| SNY Sanofi | SR147778 | Phase 2 | — | — | — |
| IONS Ionis Pharmaceuticals, Inc. | ISIS-FGFR4RX | Phase 2 | — | — | — |
| SKYE Skye Bioscience, Inc. | Nimacimab injection | Phase 2 | — | — | — |
Development Stage Distribution
Phase 3
4
Phase 2
3
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not Financial Advice
All predictions are probabilistic and based on historical data. Past performance does not guarantee future results. Consult a qualified financial advisor.